Interactive Investor

ReNeuron Q&A: biotech firm updates investors

1st December 2021 10:48

Investor Meet Company from ii contributor

CEO Olav Hellebø, chief finance officer Catherine Isted and chief scientific officer Stefano Pluchino of ReNeuron Group (LSE:RENE) present their interim results and answer a range of investor questions. The event, held on 30 November 2021, is brought to you by our friends at Investor Meet Company.


Q&A: 31:45 

About the company

ReNeuron Group is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from the UK and US. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer. Its principal business involves the research and development of stem cell technology for the treatment of motor disabilities and blindness-causing diseases.

These articles are provided for information purposes only.  Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties.  The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.

Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.